Laurence Albiges (MD, PhD) is a medical oncologist dedicated to genitourinary malignancies and her main research focus is renal cell carcinoma (RCC). She has trained and became faculty at Gustave Roussy since 2013. She is involved in the development of targeted agents and immune checkpoint blockers for metastatic RCC.  Dr Albiges is the PI of investigator-initiated and industry-sponsored phase II and phase III trials of new agents in metastatic RCC. She works in close collaboration with early drug department for phase I relevant to RCC. Throughout her training and faculty positions, she has created collaboration with major RCC clinical research centers in Europe and in the United States and built translational collaborations funded both from academic and industry support. 

Dr Albiges is heavily committed to teaching, training and mentoring in the field of medical oncology (University Paris Sud - Paris Saclay) and has launched a specific diploma (DIU) across 3 Universities focused on Genitourinary Oncology teaching for medical oncologists, urologists and radiation oncologists. She was certified with a medical pedagogy degree in 2018. She has been elected Gustave Roussy representative for Paris Sud – Medical University council since 2015 and was re-elected for a second term in 2020.

From a clinical and institutional standpoint, she has been chairing the largest academic Genito Urinary (GU) oncology group in France since 2015. The Gustave Roussy GU group manages >1100 new patients per year and enrolled over 250 patients in clinical trials in 2019. She was recently appointed vice chair of the Gustave Roussy Cancer Medicine Department as of February 2020.

She has been a member of the GETUG board since 2014, and is an active member of both the EAU RCC guidelines panel as well as the ESMO RCC guidelines panel. She is involved in the Scientific Committee of the Kidney Cancer Association.

Her research has been published in peer-reviewed journals that include Journal of Clinical Oncology, The New England Journal of Medicine, Clinical Cancer Research, European Urology, European Journal of Cancer, JAMA Oncology, and Nature Cancer.